Fresenius Kabi Oncology Limited

Pharmaceutical company specializing in oncology products, including injectables and oral cytotoxics.

2003 | Delhi (India) | Active
Last Updated:

Fresenius Kabi Oncology Profile

Key Indicators

  • Authorised Capital ₹ 50.00 Cr
  • Paid Up Capital ₹ 48.04 Cr
  • Company Age 22 Year, 1 Month
  • Last Filing with ROC 31 Mar 2024
  • Satisfied Charges ₹ 240.70 Cr
  • Revenue Growth 7.09%
  • Profit Growth 27.35%
  • Ebitda -4.37%
  • Net Worth 3.98%
  • Total Assets 13.65%

About Fresenius Kabi Oncology

Fresenius Kabi Oncology Limited (FKOL) is a leading Public Limited Indian Non-Government Company incorporated in India on 18 March 2003 and has a history of 22 years and one month. Its registered office is in Delhi, India.

The Corporate was formerly known as Dabur Pharma Limited. The Company is engaged in the Pharma Industry.

The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 50.00 Cr and a paid-up capital of Rs 48.04 Cr.

The company has closed loans amounting to ₹240.70 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.

The Key Managerial Personnel (KMP) at Fresenius Kabi Oncology Limited India are Nikhil Kulshreshtha as COMPANY SECRETARY and Rahul Sharma as Cfo. Uday Shetty, Nikhil Kulshreshtha, Arvind Sharma, and Three other members serve as directors at the Company.

Company Details

  • Location

    Delhi, India

  • Telephone

    +91-XXXXXXXXXX

  • Email Address

  • Website

  • Social Media

Corporate Identity Details

  • CIN/LLPIN

    U24231DL2003PLC119441

  • Company No.

    119441

  • Company Classification

    Public Limited Indian Non-Government Company

  • Incorporation Date

    18 Mar 2003

  • Date of AGM

    27 Aug 2024

  • Date of Balance Sheet

    31 Mar 2024

  • Listing Status

    Unlisted

  • ROC Code

    Roc Delhi

Industry

Pharma

What products or services does Fresenius Kabi Oncology Limited offer?

Fresenius Kabi Oncology Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Dacogen, Injectable Products, Oncology Drug, Pharmaceutical Medicine, Hearing Aids, BTE Hearing Aids.

Company report

Fresenius Kabi Oncology Limited

Explore comprehensive data for Fresenius Kabi Oncology Limited, including financials, compliance details, shareholding patterns, and litigation history.

Who are the key members and board of directors at Fresenius Kabi Oncology?

Executive Team (3)

NameDesignationAppointment DateStatus
Arvind Sharma Country flag representing In Managing Director01-Jul-2018Current
Nikhil Kulshreshtha Country flag representing In Company Secretary21-Jul-2007Current
Rahul Sharma CFO07-Mar-2022Current

Board Members (5)

NameDesignationAppointment DateStatus
Uday Shetty Country flag representing In Director 10-May-2019Current
Nikhil Kulshreshtha Country flag representing In Whole-Time Director and Company Secretary 01-Jul-2015Current
Marc Mahl Country flag representing De Director 29-Aug-2023Current
Maximilian Bohmer Country flag representing De Director 29-Aug-2023Current
Heike Dawen Director 02-Jul-2024Current

Financial Performance of Fresenius Kabi Oncology.

Fresenius Kabi Oncology Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.09% increase. The company also saw a substantial improvement in profitability, with a 27.35% increase in profit. The company's net worth moved up by a moderate rise of 3.98%.

Fresenius Kabi Oncology revenue growth over time
Fresenius Kabi Oncology profit and loss trends over time
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023)YOY Growth
(FY 2022)(FY 2021)(FY 2020)(FY 2019)
Total Revenue
7.09%
Revenue from Operations
7.47%
Total Assets
13.65%
Profit or Loss
27.35%
Net Worth
3.98%
EBITDA
-4.37%

What is the Ownership and Shareholding Structure of Fresenius Kabi Oncology?

In 2023, Fresenius Kabi Oncology had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Indicator graph

Charges (Loans)

Open Charges

₹0

Satisfied Charges

₹240.70 Cr

Charges Breakdown by Lending Institutions

  • Idbi Bank Limited (Lead Bank) : 139.70 Cr
  • Hsbc Bank Plc : 67.00 Cr
  • Idbi Bank Limited : 19.00 Cr
  • Punjab National Bank : 15.00 Cr

Latest Charge Details

DateLenderAmountStatus
29 Sep 2008Idbi Bank Limited₹19.00 CrSatisfied
16 Jul 2008Punjab National Bank₹15.00 CrSatisfied
29 Sep 2006Hsbc Bank Plc₹67.00 CrSatisfied
31 Dec 2003Idbi Bank Limited (Lead Bank)₹139.70 CrSatisfied

How Many Employees Work at Fresenius Kabi Oncology?

Fresenius Kabi Oncology has a workforce of 1165 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee growth trends for Fresenius Kabi Oncology Limited

Deals i

Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Fresenius Kabi Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fresenius Kabi Oncology's trajectory.

Rating

Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Latest Updates, News, and FAQs on Fresenius Kabi Oncology

Recent activity within the organization

  • Annual General Meeting

    Fresenius Kabi Oncology Limited last Annual general meeting of members was held on 27 Aug 2024 as per latest MCA records.

  • Director Appointment

    Heike Susanne Van Dawen was appointed as a Director was appointed as a Director on 02 Jul 2024 & has been associated with this company since 10 months 2 days .

  • Balance Sheet

    Fresenius Kabi Oncology Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.

  • Director Appointment

    Marc Alexander Mahl was appointed as a Director was appointed as a Director on 29 Aug 2023 & has been associated with this company since 1 year 8 months .

  • Charges

    A charge registered on 29 Sep 2008 via Charge ID 10125679 with Idbi Bank Limited was fully satisfied on 21 Jul 2020.

  • Charges

    A charge with Idbi Bank Limited of Rs. 19.00 Cr registered on 29 Sep 2008 with Charge ID 10125679 was modified on 09 Aug 2019.

Frequently asked questions

  • What is the Incorporation or founding date of Fresenius Kabi Oncology Limited?

    Fresenius Kabi Oncology Limited was incorporated on 18 Mar 2003.

  • What is authorized share capital and paid-up capital of Fresenius Kabi Oncology Limited?

    The authorized share capital of Fresenius Kabi Oncology Limited is ₹ 50.00 Cr and paid-up capital is ₹ 48.04 Cr.

  • Who are the current board members & directors of Fresenius Kabi Oncology Limited?

    Currently 8 directors are associated with Fresenius Kabi Oncology Limited.

    • Uday Chandrashekhar Shetty
    • Nikhil Kulshreshtha
    • Arvind Kumar Sharma
    • Marc Alexander Mahl
    • Maximilian Alexander Bohmer
    • Heike Susanne Van Dawen
    • Nikhil Kulshreshtha
    • Rahul Sharma

  • What is the registered address of Fresenius Kabi Oncology Limited?

    As per Ministry of Corporate Affairs (Mca), the registered address of Fresenius Kabi Oncology Limited is B- 310, Som Datt Chambers - I Bhikaji Cama Place India, New Delhi, 110066.

  • What is the corporate identification number (CIN) and company number of Fresenius Kabi Oncology Limited?

    The corporate identification number (CIN) of Fresenius Kabi Oncology Limited is U24231DL2003PLC119441 and the company number is 119441 as per Ministry of Corporate Affairs (MCA).

  • What is the official website of Fresenius Kabi Oncology Limited?

    The Official website of Fresenius Kabi Oncology Limited is https://www.fresenius-kabi-oncology.com

  • What has been the recent revenue trend for Fresenius Kabi Oncology Limited?

    According to the financial reports for the fiscal year 2023, the revenue trend for Fresenius Kabi Oncology Limited has risen by 7.09%.

  • How many employees does Fresenius Kabi Oncology Limited currently have?

    As Per 2023 financial reports, 1165 employees are currently employed by Fresenius Kabi Oncology Limited.

  • What change has been observed in the net worth of Fresenius Kabi Oncology Limited, and by what percentage?

    The financial reports for the fiscal year 2023 indicates that The net worth of Fresenius Kabi Oncology Limited has experienced an upsurge of 3.98%.

  • When was the last Balance Sheet of Fresenius Kabi Oncology Limited filed with the ROC?

    The most recent Balance Sheet for Fresenius Kabi Oncology Limited was filed with the ROC on 31 Mar 2024.

Unlock Business Insights – Explore Instantly!

Search company & director profiles for free and gain access to critical business data.

  • 3.1M+ Companies
  • 15M+ Legal Cases
  • 525K+ Credit Ratings
  • 5.8M+ Directors & KMP
  • 750K+ Regulatory Alerts
  • 1.1M+ Companies' Financial Records
Start Free Trial

People also Viewed

Similar Companies Based on Drug Formulation & Development